Parkinson's disease (PD) primarily results from a substantial loss of dopaminergic neurons in the midbrain. Despite extensive studies, the mechanisms underlying the neuron death in PD remain unknown. A limited understanding on the disease mechanisms is a major roadblock in the development of PD therapy. Dopamine as the specified neurotransmitter has long been suspected as a potential determinant of neurodegeneration in PD. In the dopaminergic neurons, free dopamine in the cytosol is a unique source of endogenous toxins leading to neuron death;however, dopamine of physiological concentration is not sufficient to cause cell death. Dopamine may become toxic when other risk factors coexist. Aging is a high risk factor for PD. Physiological changes during the aging may compromise cell protection machinery, increasing the sensitivity of dopaminergic neurons to chronic dopamine toxicity. While most PD cases are sporadic, about 10% of the cases are caused by pathogenic mutations in individual genes. While pathogenic mutations in the alpha-synuclein or the LRRK2 gene gain toxic properties, mutations in the neuron-protective genes (i.e. parkin, DJ-1 and PINK1) abolish protective effects of the genes. How these disease genes play their roles in sporadic PD remains to be elucidated. In PD, dopaminergic neuron death might be a final accumulative effect of multiple risky factors such as chronic dopamine toxicity, physiological changes during aging, gain of toxic properties for neurotoxic genes, or loss of protective functions for neuron-protective genes. To test proposed mechanisms of dopaminergic neuron death in PD, we have created two novel mouse lines: DAT-CreERT2 transgenic mouse and conditional VMAT2 knockout mouse. With the existing novel mouse models, we will assess the enhancing effect of aging on chronic dopamine toxicity and assess the accumulative adverse effect of chronic dopamine toxicity and mutations in the alpha-synuclein on dopaminergic cell survival in compound mouse models. The results from these studies would advance the understanding on the disease mechanisms and would guide the development of PD therapy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
1R01NS064042-01A2
Application #
7739392
Study Section
Clinical Neuroplasticity and Neurotransmitters Study Section (CNNT)
Program Officer
Sutherland, Margaret L
Project Start
2009-08-01
Project End
2011-07-31
Budget Start
2009-08-01
Budget End
2010-07-31
Support Year
1
Fiscal Year
2009
Total Cost
$356,275
Indirect Cost
Name
Thomas Jefferson University
Department
Pathology
Type
Schools of Medicine
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Huang, Cao; Tong, Jianbin; Bi, Fangfang et al. (2012) Mutant TDP-43 in motor neurons promotes the onset and progression of ALS in rats. J Clin Invest 122:107-18
Zhou, Hongxia; Huang, Cao; Tong, Jianbin et al. (2011) Early exposure to paraquat sensitizes dopaminergic neurons to subsequent silencing of PINK1 gene expression in mice. Int J Biol Sci 7:1180-7
Tian, Tian; Huang, Cao; Tong, Jianbin et al. (2011) TDP-43 potentiates alpha-synuclein toxicity to dopaminergic neurons in transgenic mice. Int J Biol Sci 7:234-43
Zhou, Hongxia; Huang, Cao; Tong, Jianbin et al. (2011) Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake. Int J Biol Sci 7:753-61